Intrinsic value of BioTelemetry - BEAT

Previous Close

$56.25

  Intrinsic Value

$108.70

stock screener

  Rating & Target

str. buy

+93%

Previous close

$56.25

 
Intrinsic value

$108.70

 
Up/down potential

+93%

 
Rating

str. buy

We calculate the intrinsic value of BEAT stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.8

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  459
  709
  1,060
  1,538
  2,170
  2,984
  4,005
  5,259
  6,767
  8,547
  10,613
  12,976
  15,640
  18,609
  21,880
  25,452
  29,319
  33,474
  37,911
  42,623
  47,604
  52,849
  58,354
  64,116
  70,135
  76,411
  82,947
  89,747
  96,818
  104,167
Variable operating expenses, $m
  397
  594
  870
  1,245
  1,742
  2,381
  3,183
  4,169
  5,354
  6,752
  8,340
  10,196
  12,290
  14,622
  17,193
  20,000
  23,038
  26,303
  29,790
  33,493
  37,407
  41,528
  45,854
  50,382
  55,111
  60,043
  65,179
  70,522
  76,078
  81,853
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  397
  594
  870
  1,245
  1,742
  2,381
  3,183
  4,169
  5,354
  6,752
  8,340
  10,196
  12,290
  14,622
  17,193
  20,000
  23,038
  26,303
  29,790
  33,493
  37,407
  41,528
  45,854
  50,382
  55,111
  60,043
  65,179
  70,522
  76,078
  81,853
Operating income, $m
  62
  115
  191
  293
  428
  603
  821
  1,090
  1,413
  1,794
  2,273
  2,780
  3,350
  3,986
  4,687
  5,452
  6,280
  7,170
  8,121
  9,130
  10,197
  11,321
  12,500
  13,734
  15,024
  16,368
  17,768
  19,225
  20,739
  22,314
EBITDA, $m
  124
  192
  288
  417
  589
  809
  1,086
  1,426
  1,835
  2,318
  2,878
  3,519
  4,242
  5,047
  5,934
  6,903
  7,952
  9,078
  10,282
  11,560
  12,911
  14,333
  15,826
  17,389
  19,021
  20,724
  22,496
  24,340
  26,258
  28,251
Interest expense (income), $m
  0
  11
  20
  33
  51
  76
  108
  150
  203
  267
  345
  437
  543
  665
  802
  955
  1,124
  1,308
  1,507
  1,721
  1,950
  2,193
  2,449
  2,720
  3,003
  3,300
  3,610
  3,934
  4,271
  4,621
  4,985
Earnings before tax, $m
  51
  95
  158
  242
  353
  495
  671
  887
  1,146
  1,449
  1,837
  2,236
  2,685
  3,184
  3,732
  4,328
  4,973
  5,663
  6,400
  7,180
  8,005
  8,872
  9,780
  10,731
  11,723
  12,758
  13,834
  14,954
  16,118
  17,328
Tax expense, $m
  14
  26
  43
  65
  95
  134
  181
  240
  309
  391
  496
  604
  725
  860
  1,008
  1,169
  1,343
  1,529
  1,728
  1,939
  2,161
  2,395
  2,641
  2,897
  3,165
  3,445
  3,735
  4,038
  4,352
  4,679
Net income, $m
  37
  70
  115
  177
  258
  361
  490
  648
  836
  1,058
  1,341
  1,633
  1,960
  2,324
  2,724
  3,160
  3,630
  4,134
  4,672
  5,242
  5,843
  6,476
  7,140
  7,834
  8,558
  9,313
  10,099
  10,917
  11,766
  12,650

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  839
  1,296
  1,938
  2,812
  3,968
  5,455
  7,322
  9,614
  12,370
  15,625
  19,403
  23,721
  28,592
  34,019
  40,001
  46,530
  53,599
  61,195
  69,307
  77,921
  87,028
  96,617
  106,680
  117,215
  128,218
  139,691
  151,640
  164,072
  176,998
  190,433
Adjusted assets (=assets-cash), $m
  839
  1,296
  1,938
  2,812
  3,968
  5,455
  7,322
  9,614
  12,370
  15,625
  19,403
  23,721
  28,592
  34,019
  40,001
  46,530
  53,599
  61,195
  69,307
  77,921
  87,028
  96,617
  106,680
  117,215
  128,218
  139,691
  151,640
  164,072
  176,998
  190,433
Revenue / Adjusted assets
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
  0.547
Average production assets, $m
  235
  364
  544
  789
  1,113
  1,531
  2,055
  2,698
  3,471
  4,385
  5,445
  6,656
  8,023
  9,546
  11,225
  13,057
  15,040
  17,172
  19,448
  21,866
  24,421
  27,112
  29,936
  32,892
  35,979
  39,199
  42,552
  46,040
  49,668
  53,438
Working capital, $m
  15
  23
  34
  49
  69
  95
  128
  168
  217
  273
  340
  415
  500
  595
  700
  814
  938
  1,071
  1,213
  1,364
  1,523
  1,691
  1,867
  2,052
  2,244
  2,445
  2,654
  2,872
  3,098
  3,333
Total debt, $m
  369
  608
  943
  1,399
  2,002
  2,778
  3,753
  4,949
  6,388
  8,087
  10,059
  12,314
  14,856
  17,689
  20,811
  24,220
  27,910
  31,875
  36,109
  40,606
  45,360
  50,365
  55,618
  61,117
  66,861
  72,850
  79,087
  85,576
  92,324
  99,337
Total liabilities, $m
  438
  677
  1,012
  1,468
  2,071
  2,847
  3,822
  5,018
  6,457
  8,156
  10,128
  12,383
  14,925
  17,758
  20,880
  24,289
  27,979
  31,944
  36,178
  40,675
  45,429
  50,434
  55,687
  61,186
  66,930
  72,919
  79,156
  85,645
  92,393
  99,406
Total equity, $m
  401
  619
  926
  1,344
  1,897
  2,607
  3,500
  4,595
  5,913
  7,469
  9,274
  11,339
  13,667
  16,261
  19,120
  22,241
  25,620
  29,251
  33,129
  37,246
  41,599
  46,183
  50,993
  56,029
  61,288
  66,772
  72,484
  78,426
  84,605
  91,027
Total liabilities and equity, $m
  839
  1,296
  1,938
  2,812
  3,968
  5,454
  7,322
  9,613
  12,370
  15,625
  19,402
  23,722
  28,592
  34,019
  40,000
  46,530
  53,599
  61,195
  69,307
  77,921
  87,028
  96,617
  106,680
  117,215
  128,218
  139,691
  151,640
  164,071
  176,998
  190,433
Debt-to-equity ratio
  0.920
  0.980
  1.020
  1.040
  1.060
  1.070
  1.070
  1.080
  1.080
  1.080
  1.080
  1.090
  1.090
  1.090
  1.090
  1.090
  1.090
  1.090
  1.090
  1.090
  1.090
  1.090
  1.090
  1.090
  1.090
  1.090
  1.090
  1.090
  1.090
  1.090
Adjusted equity ratio
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478
  0.478

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  37
  70
  115
  177
  258
  361
  490
  648
  836
  1,058
  1,341
  1,633
  1,960
  2,324
  2,724
  3,160
  3,630
  4,134
  4,672
  5,242
  5,843
  6,476
  7,140
  7,834
  8,558
  9,313
  10,099
  10,917
  11,766
  12,650
Depreciation, amort., depletion, $m
  63
  77
  97
  124
  160
  207
  265
  336
  422
  524
  605
  740
  891
  1,061
  1,247
  1,451
  1,671
  1,908
  2,161
  2,430
  2,713
  3,012
  3,326
  3,655
  3,998
  4,355
  4,728
  5,116
  5,519
  5,938
Funds from operations, $m
  100
  147
  212
  301
  418
  568
  755
  984
  1,259
  1,582
  1,946
  2,372
  2,852
  3,385
  3,971
  4,610
  5,301
  6,042
  6,833
  7,671
  8,557
  9,489
  10,466
  11,488
  12,556
  13,669
  14,827
  16,032
  17,285
  18,587
Change in working capital, $m
  6
  8
  11
  15
  20
  26
  33
  40
  48
  57
  66
  76
  85
  95
  105
  114
  124
  133
  142
  151
  159
  168
  176
  184
  193
  201
  209
  218
  226
  235
Cash from operations, $m
  94
  139
  201
  286
  398
  542
  722
  944
  1,210
  1,525
  1,880
  2,297
  2,767
  3,290
  3,867
  4,496
  5,177
  5,909
  6,691
  7,520
  8,397
  9,321
  10,290
  11,304
  12,363
  13,468
  14,618
  15,815
  17,059
  18,352
Maintenance CAPEX, $m
  -16
  -26
  -40
  -60
  -88
  -124
  -170
  -228
  -300
  -386
  -487
  -605
  -740
  -891
  -1,061
  -1,247
  -1,451
  -1,671
  -1,908
  -2,161
  -2,430
  -2,713
  -3,012
  -3,326
  -3,655
  -3,998
  -4,355
  -4,728
  -5,116
  -5,519
New CAPEX, $m
  -88
  -128
  -180
  -245
  -324
  -417
  -524
  -643
  -774
  -913
  -1,060
  -1,212
  -1,367
  -1,523
  -1,678
  -1,832
  -1,984
  -2,132
  -2,276
  -2,417
  -2,555
  -2,691
  -2,824
  -2,956
  -3,088
  -3,220
  -3,353
  -3,488
  -3,627
  -3,770
Cash from investing activities, $m
  -104
  -154
  -220
  -305
  -412
  -541
  -694
  -871
  -1,074
  -1,299
  -1,547
  -1,817
  -2,107
  -2,414
  -2,739
  -3,079
  -3,435
  -3,803
  -4,184
  -4,578
  -4,985
  -5,404
  -5,836
  -6,282
  -6,743
  -7,218
  -7,708
  -8,216
  -8,743
  -9,289
Free cash flow, $m
  -10
  -16
  -20
  -20
  -14
  1
  28
  72
  137
  226
  332
  480
  660
  876
  1,128
  1,417
  1,743
  2,107
  2,507
  2,942
  3,413
  3,917
  4,453
  5,022
  5,621
  6,250
  6,910
  7,598
  8,316
  9,063
Issuance/(repayment) of debt, $m
  164
  239
  335
  456
  603
  776
  975
  1,196
  1,439
  1,699
  1,972
  2,254
  2,543
  2,833
  3,122
  3,408
  3,690
  3,965
  4,234
  4,497
  4,754
  5,005
  5,253
  5,499
  5,744
  5,989
  6,237
  6,489
  6,747
  7,013
Issuance/(repurchase) of shares, $m
  113
  149
  192
  241
  295
  350
  402
  448
  481
  498
  465
  432
  368
  270
  135
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  277
  388
  527
  697
  898
  1,126
  1,377
  1,644
  1,920
  2,197
  2,437
  2,686
  2,911
  3,103
  3,257
  3,408
  3,690
  3,965
  4,234
  4,497
  4,754
  5,005
  5,253
  5,499
  5,744
  5,989
  6,237
  6,489
  6,747
  7,013
Total cash flow (excl. dividends), $m
  267
  372
  507
  677
  883
  1,126
  1,405
  1,717
  2,057
  2,422
  2,769
  3,166
  3,571
  3,978
  4,385
  4,825
  5,433
  6,072
  6,741
  7,439
  8,166
  8,922
  9,707
  10,521
  11,365
  12,240
  13,147
  14,087
  15,063
  16,076
Retained Cash Flow (-), $m
  -150
  -219
  -307
  -418
  -552
  -711
  -892
  -1,096
  -1,318
  -1,556
  -1,806
  -2,064
  -2,328
  -2,594
  -2,859
  -3,121
  -3,379
  -3,631
  -3,877
  -4,118
  -4,353
  -4,583
  -4,811
  -5,035
  -5,259
  -5,484
  -5,711
  -5,942
  -6,179
  -6,422
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  117
  153
  200
  259
  331
  416
  513
  621
  740
  867
  964
  1,102
  1,242
  1,384
  1,526
  1,704
  2,054
  2,441
  2,863
  3,321
  3,813
  4,339
  4,896
  5,485
  6,105
  6,755
  7,435
  8,145
  8,885
  9,654
Discount rate, %
  7.10
  7.46
  7.83
  8.22
  8.63
  9.06
  9.51
  9.99
  10.49
  11.01
  11.57
  12.14
  12.75
  13.39
  14.06
  14.76
  15.50
  16.27
  17.09
  17.94
  18.84
  19.78
  20.77
  21.81
  22.90
  24.04
  25.25
  26.51
  27.83
  29.22
PV of cash for distribution, $m
  109
  133
  160
  189
  219
  247
  271
  290
  301
  305
  289
  278
  261
  238
  212
  188
  177
  162
  143
  122
  102
  82
  64
  48
  35
  25
  17
  11
  7
  4
Current shareholders' claim on cash, %
  94.2
  89.7
  86.0
  83.1
  80.7
  78.7
  77.1
  75.8
  74.7
  73.9
  73.2
  72.8
  72.5
  72.3
  72.2
  72.2
  72.2
  72.2
  72.2
  72.2
  72.2
  72.2
  72.2
  72.2
  72.2
  72.2
  72.2
  72.2
  72.2
  72.2

BioTelemetry, Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The company operates in three segments: Healthcare, Research, and Technology. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. It offers Mobile Cardiac Outpatient Telemetry and External Cardiac Ambulatory Telemetry services, which incorporates a lightweight patient-worn sensor attached to electrodes that capture two-channel electrocardiography (ECG) data, measuring electrical activity of the heart, on a compact wireless handheld monitor; event monitoring services to prescribe wireless event monitors, digital loop event monitors, memory loop event monitors, and non-loop event monitors; and a Holter and extended-wear Holter monitors to cardiologists and electrophysiologists. The Research Services segment provides cardiac monitoring, imaging, scientific consulting, and data management services for drug, medical treatment, and device trials to pharmaceutical companies and contract research organizations. Its centralized services include ECG, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, and expert reporting and statistical analysis. This segment also offers services in the cardiovascular, oncology, musculoskeletal, and neurologic therapeutic areas; and support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Technology segment focuses on the manufacture, engineering, and development of non-invasive cardiac monitors for healthcare companies, clinics, and hospitals worldwide. This segment offers various devices, including cardiac event monitors, digital Holter monitors, and mobile cardiac telemetry monitors. BioTelemetry, Inc. is headquartered in Malvern, Pennsylvania.

FINANCIAL RATIOS  of  BioTelemetry (BEAT)

Valuation Ratios
P/E Ratio 0
Price to Sales 0
Price to Book 0
Price to Tangible Book
Price to Cash Flow 0
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio NaN
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 0%
Ret/ On Assets - 3 Yr. Avg. 0%
Return On Total Capital 0%
Ret/ On T. Cap. - 3 Yr. Avg. 0%
Return On Equity 0%
Return On Equity - 3 Yr. Avg. 0%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 0%
EBITDA Margin - 3 Yr. Avg. 0%
Operating Margin 0%
Oper. Margin - 3 Yr. Avg. 0%
Pre-Tax Margin 0%
Pre-Tax Margin - 3 Yr. Avg. 0%
Net Profit Margin 0%
Net Profit Margin - 3 Yr. Avg. 0%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

BEAT stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the BEAT stock intrinsic value calculation we used $286.776 million for the last fiscal year's total revenue generated by BioTelemetry. The default revenue input number comes from 0001 income statement of BioTelemetry. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our BEAT stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 7.1%, whose default value for BEAT is calculated based on our internal credit rating of BioTelemetry, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of BioTelemetry.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of BEAT stock the variable cost ratio is equal to 91.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for BEAT stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for BioTelemetry.

Corporate tax rate of 27% is the nominal tax rate for BioTelemetry. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the BEAT stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for BEAT are equal to 51.3%.

Life of production assets of 9 years is the average useful life of capital assets used in BioTelemetry operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for BEAT is equal to 3.2%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $250.757 million for BioTelemetry - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 32.726 million for BioTelemetry is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of BioTelemetry at the current share price and the inputted number of shares is $1.8 billion.

COMPANY NEWS

▶ 10 Triple-A Stocks to Buy for the Rest of 2018   [Sep-28-18 02:53PM  InvestorPlace]
▶ 7 Market-Beating Stocks to Buy to Weather a Trade War   [Sep-21-18 01:59PM  InvestorPlace]
▶ Is It Time To Consider Buying BioTelemetry Inc (NASDAQ:BEAT)?   [Sep-18-18 12:51PM  Simply Wall St.]
▶ [$$] ActiveCare Makes Peace With Creditor Group   [Aug-17-18 04:49PM  The Wall Street Journal]
▶ [$$] ActiveCare Creditors Group Wants Sales Process Extended   [Aug-10-18 02:59PM  The Wall Street Journal]
▶ 4 Top Stocks to Buy on Blockbuster Earnings Growth   [Jul-31-18 01:25PM  InvestorPlace]
▶ Here's Why BioTelemetry Rose as Much as 17.5% Today   [Jul-26-18 03:55PM  Motley Fool]
▶ BioTelemetry: 2Q Earnings Snapshot   [Jul-25-18 06:14PM  Associated Press]
▶ NovoCure (NVCR) Catches Eye: Stock Jumps 7.4%   [Jul-17-18 08:54AM  Zacks]
▶ [$$] Diabetes Monitoring Company ActiveCare Files for Bankruptcy   [Jul-16-18 02:22PM  The Wall Street Journal]
▶ Natera (NTRA) Catches Eye: Stock Jumps 6.3%   [Jul-13-18 08:49AM  Zacks]
▶ 18 Midterm Election Year Stock Picks   [Jul-09-18 07:23AM  Investopedia]
▶ Tech Rally Ends NASDAQ's 5-Day Slide   [Apr-27-18 09:15AM  Zacks]
▶ BioTelemetry: 1Q Earnings Snapshot   [Apr-25-18 05:32PM  Associated Press]
▶ Healthcare and biotech investor Sami Hamade dies   [Apr-09-18 04:54PM  American City Business Journals]
▶ BioTelemetry reports 4Q loss   [Feb-22-18 07:53PM  Associated Press]
▶ BioTelemetry Q4 Earnings Preview   [10:15AM  Benzinga]
▶ Stocks Showing Improved Relative Strength: BioTelemetry   [Dec-20-17 03:00AM  Investor's Business Daily]
▶ Apple Doesn't Need Next Big Thing For A While, Analyst Says   [Nov-30-17 04:31PM  Investor's Business Daily]
▶ BioTelemetry reports 3Q loss   [Nov-07-17 05:39PM  Associated Press]
▶ Stocks With Rising Relative Strength: BioTelemetry   [Oct-27-17 03:00AM  Investor's Business Daily]
▶ BioTelemetry: Cramer's Top Takeaways   [Oct-04-17 06:45AM  TheStreet.com]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.